Prothrombogenic microvasculature and transplant outcome

Carlos A. Labarrere, David R. Nelson, Steven Miller

Research output: Contribution to journalArticle

Abstract

A major obstacle to the long-term success of transplanted solid organs is the development of transplant-associated vasculopathy. A prime risk factor for the development of vascular disease is the conversion of the microvasculature from a thromboresistant to a prothrombogenic state, leading to fibrin deposition. A thromboresistant microvasculature is characterized by vessels in which the endothelium has intact natural anticoagulant and fibrinolytic pathways and by the lack of activated endothelial cells. A prothrombogenic microvasculature results when there are failures in anticoagulant pathways, such as the protein C and the vascular antithrombin pathways, or when there is an absence of fibrinolytic activity, as when tissue plasminogen activator is depleted. Activated endothelium, characterized by increased arterial expression of moieties such as intercellular adhesion molecule-1 and human leukocyte antigen-DR, also is associated with a prothrombogenic microvasculature. The presence of a prothrombogenic microvasculature early after transplantation is associated with an increased incidence of both coronary artery disease and chronic graft failure. Although the mechanisms responsible for the loss of thromboresistant endothelium are unclear, the fact that changes in the anticoagulant, fibrinolytic, and activational status of endothelial cells may occur early after transplantation suggests a peritransplant phenomenon as an initiating event. The use of both new and established therapies to inhibit the formation of a prothrombogenic microvasculature could slow the development of transplant coronary artery disease and significantly improve allograft survival.

Original languageEnglish
Pages (from-to)212-222
Number of pages11
JournalGraft
Volume5
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Microvessels
Transplants
Anticoagulants
Endothelium
Coronary Artery Disease
Endothelial Cells
Transplantation
Antithrombins
Tissue Plasminogen Activator
Intercellular Adhesion Molecule-1
HLA Antigens
Protein C
Fibrin
Vascular Diseases
Allografts
Blood Vessels
Incidence

ASJC Scopus subject areas

  • Transplantation

Cite this

Prothrombogenic microvasculature and transplant outcome. / Labarrere, Carlos A.; Nelson, David R.; Miller, Steven.

In: Graft, Vol. 5, No. 4, 2002, p. 212-222.

Research output: Contribution to journalArticle

Labarrere, Carlos A. ; Nelson, David R. ; Miller, Steven. / Prothrombogenic microvasculature and transplant outcome. In: Graft. 2002 ; Vol. 5, No. 4. pp. 212-222.
@article{f37e4c475f1a4cb9a3888572b269f345,
title = "Prothrombogenic microvasculature and transplant outcome",
abstract = "A major obstacle to the long-term success of transplanted solid organs is the development of transplant-associated vasculopathy. A prime risk factor for the development of vascular disease is the conversion of the microvasculature from a thromboresistant to a prothrombogenic state, leading to fibrin deposition. A thromboresistant microvasculature is characterized by vessels in which the endothelium has intact natural anticoagulant and fibrinolytic pathways and by the lack of activated endothelial cells. A prothrombogenic microvasculature results when there are failures in anticoagulant pathways, such as the protein C and the vascular antithrombin pathways, or when there is an absence of fibrinolytic activity, as when tissue plasminogen activator is depleted. Activated endothelium, characterized by increased arterial expression of moieties such as intercellular adhesion molecule-1 and human leukocyte antigen-DR, also is associated with a prothrombogenic microvasculature. The presence of a prothrombogenic microvasculature early after transplantation is associated with an increased incidence of both coronary artery disease and chronic graft failure. Although the mechanisms responsible for the loss of thromboresistant endothelium are unclear, the fact that changes in the anticoagulant, fibrinolytic, and activational status of endothelial cells may occur early after transplantation suggests a peritransplant phenomenon as an initiating event. The use of both new and established therapies to inhibit the formation of a prothrombogenic microvasculature could slow the development of transplant coronary artery disease and significantly improve allograft survival.",
author = "Labarrere, {Carlos A.} and Nelson, {David R.} and Steven Miller",
year = "2002",
doi = "10.1177/15262802005004004",
language = "English",
volume = "5",
pages = "212--222",
journal = "Graft",
issn = "1522-1628",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Prothrombogenic microvasculature and transplant outcome

AU - Labarrere, Carlos A.

AU - Nelson, David R.

AU - Miller, Steven

PY - 2002

Y1 - 2002

N2 - A major obstacle to the long-term success of transplanted solid organs is the development of transplant-associated vasculopathy. A prime risk factor for the development of vascular disease is the conversion of the microvasculature from a thromboresistant to a prothrombogenic state, leading to fibrin deposition. A thromboresistant microvasculature is characterized by vessels in which the endothelium has intact natural anticoagulant and fibrinolytic pathways and by the lack of activated endothelial cells. A prothrombogenic microvasculature results when there are failures in anticoagulant pathways, such as the protein C and the vascular antithrombin pathways, or when there is an absence of fibrinolytic activity, as when tissue plasminogen activator is depleted. Activated endothelium, characterized by increased arterial expression of moieties such as intercellular adhesion molecule-1 and human leukocyte antigen-DR, also is associated with a prothrombogenic microvasculature. The presence of a prothrombogenic microvasculature early after transplantation is associated with an increased incidence of both coronary artery disease and chronic graft failure. Although the mechanisms responsible for the loss of thromboresistant endothelium are unclear, the fact that changes in the anticoagulant, fibrinolytic, and activational status of endothelial cells may occur early after transplantation suggests a peritransplant phenomenon as an initiating event. The use of both new and established therapies to inhibit the formation of a prothrombogenic microvasculature could slow the development of transplant coronary artery disease and significantly improve allograft survival.

AB - A major obstacle to the long-term success of transplanted solid organs is the development of transplant-associated vasculopathy. A prime risk factor for the development of vascular disease is the conversion of the microvasculature from a thromboresistant to a prothrombogenic state, leading to fibrin deposition. A thromboresistant microvasculature is characterized by vessels in which the endothelium has intact natural anticoagulant and fibrinolytic pathways and by the lack of activated endothelial cells. A prothrombogenic microvasculature results when there are failures in anticoagulant pathways, such as the protein C and the vascular antithrombin pathways, or when there is an absence of fibrinolytic activity, as when tissue plasminogen activator is depleted. Activated endothelium, characterized by increased arterial expression of moieties such as intercellular adhesion molecule-1 and human leukocyte antigen-DR, also is associated with a prothrombogenic microvasculature. The presence of a prothrombogenic microvasculature early after transplantation is associated with an increased incidence of both coronary artery disease and chronic graft failure. Although the mechanisms responsible for the loss of thromboresistant endothelium are unclear, the fact that changes in the anticoagulant, fibrinolytic, and activational status of endothelial cells may occur early after transplantation suggests a peritransplant phenomenon as an initiating event. The use of both new and established therapies to inhibit the formation of a prothrombogenic microvasculature could slow the development of transplant coronary artery disease and significantly improve allograft survival.

UR - http://www.scopus.com/inward/record.url?scp=0036306137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036306137&partnerID=8YFLogxK

U2 - 10.1177/15262802005004004

DO - 10.1177/15262802005004004

M3 - Article

VL - 5

SP - 212

EP - 222

JO - Graft

JF - Graft

SN - 1522-1628

IS - 4

ER -